TeSR™-E7™ can be used during the entire induction phase of reprogramming (day 3 to 25+). Following reprogramming, iPS cell colonies can be isolated and propogated in feeder-free maintenance systems (eg. mTeSR™1 or TeSR™-E8™ media on Corning® Matrigel® or Vitronectin XF™ matrices).
Figure 2. Morphology of Representative iPS Cell Colonies Arising During the Induction Period in TeSR™-E7™
(A-B) Small clusters of colonies with an epithelial-like morphology will appear by one to two weeks following induction (see arrows). (C-D) These clusters expand into pre-iPS cell colonies by two to three weeks. (E-F) Larger ES cell-like colonies are clearly identifiable by three to four weeks. Representative colonies from adult human fibroblasts reprogrammed with episomal vectors containing OCT-4, SOX2, KLF-4, and L-MYC are shown.
Figure 3. Comparison of Primary iPS Cell Colonies Derived Using TeSR™-E7™ and KOSR-Based Medium
(A) TeSR™-E7™ generates colonies with defined borders and less overgrowth of background fibroblasts compared to (B) KOSR-based iPS cell induction medium. Representative colonies from adult human fibroblasts reprogrammed with episomal vectors containing OCT-4, SOX2, KLF-4, and L-MYC are shown.
Figure 4. Comparison of Primary iPS Cell Colonies Derived Using TeSR™-E7™ with Qualified vs Unqualified bFGF
(A) TeSR™-E7™ yields easily recognizable iPS cell colonies with defined borders. (B) Unqualified components can result in colonies that have poorly defined edges and higher levels of differentiation. Representative colonies from adult human fibroblasts reprogrammed with episomal vectors containing OCT-4, SOX2, KLF-4, and L-MYC are shown.
Figure 5. iPS Colonies Expanded in mTeSR™ or TeSR™-E8™
(A - D) iPS cell colonies generated in TeSR™-E7™ and expanded in either mTeSR™1 on Corning® Matrigel® (A-B) or TeSR™-E8™ on Vitronectin XF™ (C, D) exhibit classic ES cell morphology with dense colony centers, defined borders, prominent nucleoli and high nuclear-to-cytoplasmic ratios. (E) iPS cells express high levels of pluripotency markers after just two passages in either mTeSR™1 or TeSR™-E8™ as demonstrated by OCT-4 and SSEA-3 flow cytometry analysis. Data are expressed as mean ± SEM, n = 4.
Figure 6. TeSR™-E7™ Supports Reprogramming of Human Cell Types Including Adult Dermal Fibroblasts and Neonatal Fibroblasts
Reprogramming of (A) adult normal human dermal fibroblasts (NHDF, 33 year-old female) and (B) neonatal foreskin fibroblasts (BJ cells) with episomal reprogramming vectors are shown. TeSR™-E7™ demonstrated similar (in NHDF) or greater (in BJ cells) reprogramming efficiencies compared to KOSR-based iPS cell induction medium. TeSR™-E7™ demonstrated higher reprogramming efficiencies compared to TeSR™-E8™. Data are expressed as mean ± SEM, n ≥ 6, * p ≤ 0.05.
Figure 7. iPS Cells Derived in TeSR™-E7™ Display Normal Karyotype
iPS cell lines were generated in TeSR™-E7™ medium, maintained in mTeSR™1 or TeSR™-E8™ media for a minimum of 5 passages and karyotyped by G-banding karyotype analysis. Three iPS cell lines were analyzed and all demonstrated a normal karyotype; a representative karyogram is shown.
Figure 8. Directed Differentiation of iPS Cells to All Three Germ Layers
TeSR™-E7™-derived iPS cells were differentiated into all three germ layers. Endoderm specification was achieved using the STEMdiff™ Definitive Endoderm Kit, results demonstrated 93.6% SOX17 + CXCR4 + cells. Mesoderm specification was demonstrated using a STEMdiff™ APEL™ medium-based endothelial differentiation protocol, results demonstrated &ht;99% CD31 + cells (data not shown) and 84.8% VEGFR2 + CD105 + cells. Ectoderm specification was demonstrated using STEMdiff™ Neural Induction Medium, immunocytochemistry shows high levels of PAX6 staining with no detectable OCT-4 staining by day 9 of neural induction.
Disruption of GRIN2B Impairs Differentiation in Human Neurons. S. Bell et al. Stem cell reports 2018 JUL
Abstract
Heterozygous loss-of-function mutations in GRIN2B, a subunit of the NMDA receptor, cause intellectual disability and language impairment. We developed clonal models of GRIN2B deletion and loss-of-function mutations in a region coding for the glutamate binding domain in human cells and generated neurons from a patient harboring a missense mutation in the same domain. Transcriptome analysis revealed extensive increases in genes associated with cell proliferation and decreases in genes associated with neuron differentiation, a result supported by extensive protein analyses. Using electrophysiology and calcium imaging, we demonstrate that NMDA receptors are present on neural progenitor cells and that human mutations in GRIN2B can impair calcium influx and membrane depolarization even in a presumed undifferentiated cell state, highlighting an important role for non-synaptic NMDA receptors. It may be this function, in part, which underlies the neurological disease observed in patients with GRIN2B mutations.
Thank you for your interest in IntestiCult™ Organoid Growth Medium (Human). Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they
can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our
privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
本产品系基于WiCell™研究院(WiCell™ Research Institute)知识产权授权许可开发。本产品的出售目的仅限于基于不可转让、用途受限之许可下的研究用途(无论购买者为学术机构或营利性主体)。购买本产品并不被授予为商业用途(即,以获利为目的的任何行为,如将本产品用于制造用途、或转售本产品或使用本产品所制成的任何材料、或将本产品或使用本产品所制成的材料用于提供服务)或临床应用(即,将本产品或本产品所用材料应用于人体)而出售、使用或另行转让本产品的权利,或出于基础临床前研究应用(包括但不限于畸胎瘤试验)以外的目的,由营利性主体或与其合作,将使用本产品制造的任何材料植入动物体内的权利。
购买者若不同意前述条款和条件,应保持产品完好,将其退还出售方以获退款。